HomepagePJT • NYSE
add
PJT Partners Inc
$Â 144,26
Na sluitingstijd:(0,00%)0,00
$Â 144,26
Gesloten: 9 mei, 16:01:29 GMT-4 · USD · NYSE · Disclaimer
Vorige slotkoers
$Â 146,52
Dag-range
$Â 143,77 - $Â 147,38
Jaar-range
$Â 99,42 - $Â 190,28
Beurswaarde
3,52Â mld. USD
Gem. volume
347,27K
Koers/winst
25,38
Dividendrendement
0,69%
Primaire beurs
NYSE
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 324,33Â mln. | -1,48% |
Bedrijfskosten | 251,43Â mln. | -2,67% |
Netto inkomsten | 54,02Â mln. | 65,58% |
Netto winstmarge | 16,65 | 68,01% |
Winst per aandeel | 1,05 | 7,14% |
EBITDA | — | — |
Effectief belastingtarief | -41,05% | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 194,27Â mln. | -9,86% |
Totale activa | 1,40Â mld. | 7,29% |
Totale passiva | 572,39Â mln. | 20,85% |
Totaal aandelenvermogen | 824,31 mln. | — |
Uitstaande aandelen | 24,43 mln. | — |
Koers-boekwaardeverhouding | 24,38 | — |
Rendement op activa | 19,57% | — |
Rendement op kapitaal | — | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 54,02Â mln. | 65,58% |
Operationele kasstroom | -75,94Â mln. | -95,83% |
Kasstroom uit beleggingen | 28,03Â mln. | -53,11% |
Kasstroom uit financiering | -245,01Â mln. | -54,72% |
Nettomutatie in liquide middelen | -289,61Â mln. | -106,83% |
Vrije kasstroom | — | — |
Over
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
PJT operates businesses across strategic advisory, strategic capital markets, restructuring, shareholder advisory and capital raising. The firm has advised on over $1 trillion in M&A transactions including AbbVie's $63 billion acquisition of Allergan, T-Mobile's $59 billion merger with Sprint, and Mylan's $50 billion merger with Pfizer subsidiary, Upjohn.
The firm is headquartered in New York City, with additional offices in Boston, Chicago, Hong Kong, Houston, London, Los Angeles, Madrid, San Francisco and Sydney, and employs approximately 700 people. Wikipedia
Opgericht
2015
Website
Werknemers
1.143
